Reneo Pharmaceuticals, Inc. (RPHM)
Chart Events
Performance Outlook
| Previous Close | 2.7200 |
| Open | 2.6500 |
| Bid | 2.8000 x 1200 |
| Ask | 3.0000 x 1100 |
| Day's Range | 2.6500 - 3.0000 |
| 52 Week Range | 1.7900 - 6.0300 |
| Volume | |
| Avg. Volume | 27,590 |
| Market Cap | 71.381M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9210 |
| Earnings Date | Mar 21, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RPHM
Related Research
- Reneo Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 07/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
- GlobeNewswire
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
IRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma ConferenceDate: Wednesday, Feb. 15, 2023Location: Virtual Presentation: 3:40 p.m. EST (webcast)
- GlobeNewswire
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted mavodelpar (REN001) Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain f
- Simply Wall St.
Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
